Using biomarkers to personalize kidney disease treatment
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests if matching treatments to your specific kidney disease markers can better protect your kidneys. It looks at how well Finerenone, Dapagliflozin, and Semaglutide work alone or in a sequence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a certain level of protein in your urine (UACR between 100 and 5000).
- You are already taking a stable dose of an ACE inhibitor or ARB medication for at least 4 weeks (or cannot take them).
- You have not had a heart attack, stroke, or other heart event in the last 12 weeks.
- You do not have type 1 diabetes, severe kidney disease (eGFR under 25), or certain other conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a urine test can help doctors choose the right medicines earlier to prevent kidney and heart problems in people with type 2 diabetes. You may join if you have type 2 diabetes but no severe heart failure.
This Phase 2 study tests whether dapagliflozin can improve heart structure and function in people with chronic kidney disease (CKD). Dapagliflozin is a kidney-heart medicine that may affect how the heart changes over time, measured by heart scans.
This study compares two experimental treatments—one that reduces protein in urine and another that may help control blood sugar and weight—for people with chronic kidney disease. It aims to find safer, more effective ways to slow kidney damage.
This study tests whether taking two medications together—finerenone and semaglutide—can help protect kidney function in people with obesity and chronic kidney disease who have protein in their urine. The goal is to see if this combination is safe and effective for slowing kidney damage.
This study tests new treatments for people with long-standing type 1 diabetes who also have early signs of heart or kidney disease. The goal is to see if these treatments can help protect the heart and kidneys.
This study tests a combination of two medications (balcinrenone and dapagliflozin) to help protect your kidneys if you have moderate-to-severe chronic kidney disease. The trial evaluates whether this combination slows kidney damage and improves kidney health.
Hear when a new Chronic Kidney Disease(CKD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.